ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its
quarter ended June 30, 2023.
Fourth Quarter 2023 HighlightsAll comparisons
are to the prior year period
- Revenue increased by 23% to $1.1 billion; up 23% on a constant
currency basis
- Gross margin contracted 210 bps to
55.0%; non-GAAP gross margin contracted 200 bps to
55.8%
- Income from operations increased
8%; non-GAAP operating profit up 13%
- Operating cash flow of $237.4 million
- Diluted earnings per share of $1.56; non-GAAP diluted
earnings per share of $1.60
Full Year 2023 HighlightsAll comparisons are to
the prior year period
- Revenue increased by 18% to $4.2 billion; up 21% on a constant
currency basis
- Gross margin contracted 80 bps to
55.8%; non-GAAP gross margin contracted 120 bps to
56.5%
- Income from operations increased
13%; non-GAAP operating profit up 14%
- Operating cash flow of $693.3 million
- Diluted earnings per share of $6.09; non-GAAP diluted
earnings per share of $6.44
“ResMed’s fourth quarter and full-year 2023 results reflect
strong double-digit growth as we continue to produce and deliver
cloud-connected flow generator device volume to meet the ongoing
strong global demand from patients, accompanied by high growth of
our market-leading patient interface and software solutions,” said
Mick Farrell, Chairman and CEO of ResMed. “The combined global
supply of our cloud-connected platforms, AirSense10 and AirSense11,
have enabled us to support all available customer demand for CPAP
and APAP devices across the global market. The strong growth of our
mask and patient interfaces business was supported by new patient
setups as well as ongoing resupply activity as we focus on
increasing therapy adherence to improve patient outcomes and
quality-of-life. Our residential medicine software-as-a-service
business continues to achieve high-single-digit growth organically
expanding to solid double-digit growth including the contribution
from MEDIFOX DAN. As we turn to fiscal year 2024, our focus remains
on delivering world-leading therapy and digital health solutions so
that even more people are able to sleep better, breathe better, and
live higher-quality lives outside the hospital, preferably in their
own home. We continue to significantly grow our impact each
quarter, improving over 160 million lives in the last 12 months,
well on our way to helping 250 million lives in 2025.”
Financial Results and Operating
MetricsUnaudited; $ in millions, except for per share
amounts
|
Three Months Ended |
|
June 30,2023 |
|
June 30,2022 |
|
% Change |
|
ConstantCurrency (A) |
Revenue |
$ |
1,122.1 |
|
|
$ |
914.7 |
|
|
|
23 |
% |
|
|
23 |
% |
Gross margin |
|
55.0 |
% |
|
|
57.1 |
% |
|
|
(4 |
) |
|
|
Non-GAAP gross
margin (B) |
|
55.8 |
% |
|
|
57.8 |
% |
|
|
(4 |
) |
|
|
Selling, general, and
administrative expenses |
|
240.7 |
|
|
|
193.0 |
|
|
|
25 |
|
|
|
26 |
|
Research and development
expenses |
|
78.1 |
|
|
|
64.3 |
|
|
|
21 |
|
|
|
23 |
|
Income from operations |
|
275.3 |
|
|
|
255.4 |
|
|
|
8 |
|
|
|
Non-GAAP income from
operations (B) |
|
307.0 |
|
|
|
271.5 |
|
|
|
13 |
|
|
|
Net income |
|
229.7 |
|
|
|
195.1 |
|
|
|
18 |
|
|
|
Non-GAAP net
income (B) |
|
235.5 |
|
|
|
219.2 |
|
|
|
7 |
|
|
|
Diluted earnings per
share |
$ |
1.56 |
|
|
$ |
1.33 |
|
|
|
17 |
|
|
|
Non-GAAP diluted earnings
per share (B) |
$ |
1.60 |
|
|
$ |
1.49 |
|
|
|
7 |
|
|
|
|
Twelve Months Ended |
|
June 30,2023 |
|
June 30,2022 |
|
% Change |
|
ConstantCurrency (A) |
Revenue |
$ |
4,223.0 |
|
|
$ |
3,578.1 |
|
|
|
18 |
% |
|
|
21 |
% |
Gross margin |
|
55.8 |
% |
|
|
56.6 |
% |
|
|
(1 |
) |
|
|
Non-GAAP gross
margin (B) |
|
56.5 |
% |
|
|
57.7 |
% |
|
|
(2 |
) |
|
|
Selling, general, and
administrative expenses |
|
874.0 |
|
|
|
737.5 |
|
|
|
19 |
|
|
|
22 |
|
Research and development
expenses |
|
287.6 |
|
|
|
253.6 |
|
|
|
13 |
|
|
|
16 |
|
Income from operations |
|
1,131.9 |
|
|
|
1,000.3 |
|
|
|
13 |
|
|
|
Non-GAAP income from
operations (B) |
|
1,224.4 |
|
|
|
1,072.9 |
|
|
|
14 |
|
|
|
Net income |
|
897.6 |
|
|
|
779.4 |
|
|
|
15 |
|
|
|
Non-GAAP net
income (B) |
|
949.8 |
|
|
|
850.8 |
|
|
|
12 |
|
|
|
Diluted earnings per
share |
$ |
6.09 |
|
|
$ |
5.30 |
|
|
|
15 |
|
|
|
Non-GAAP diluted earnings
per share (B) |
$ |
6.44 |
|
|
$ |
5.79 |
|
|
|
11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(A) In order to provide a framework for assessing how our
underlying businesses performed excluding the effect of foreign
currency fluctuations, we provide certain financial information on
a “constant currency” basis, which is in addition to the actual
financial information presented. In order to calculate our constant
currency information, we translate the current period financial
information using the foreign currency exchange rates that were in
effect during the previous comparable period. However, constant
currency measures should not be considered in isolation or as an
alternative to U.S. dollar measures that reflect current period
exchange rates, or to other financial measures calculated and
presented in accordance with U.S. GAAP.
(B) See the reconciliation of non-GAAP financial
measures in the table at the end of the press release.
Discussion of Fourth Quarter ResultsAll
comparisons are to the prior year period unless otherwise noted
- Revenue grew by 23 percent on a constant currency basis,
driven by increased demand for our sleep and respiratory care
devices as well as reduced competitive supply.
- Revenue in the U.S., Canada, and Latin America, excluding
Software-as-a-Service, grew by 25 percent, primarily due to the
factors discussed above.
- Revenue in Europe, Asia, and other markets, excluding
Software-as-a-Service, grew by 14 percent on a constant
currency basis.
- Software-as-a-Service revenue increased by 34 percent,
reflecting incremental revenue from our acquisition of MEDIFOX DAN
and continued organic growth in our SaaS portfolio.
- Gross margin decreased by 210 basis points
and non-GAAP gross margin decreased by 200 basis points,
mainly due to unfavorable product mix and higher component and
manufacturing costs, partially offset by an increase in average
selling prices.
- Selling, general, and administrative expenses increased by
26 percent on a constant currency basis. SG&A expenses
increased to 21.5 percent of revenue in the quarter, compared
with 21.1 percent in the same period of the prior year. These
changes in SG&A expenses were mainly due to increases in
employee-related expenses and incremental expense associated with
our acquisition of MEDIFOX DAN.
- Income from operations increased by 8 percent
and non-GAAP income from operations increased by 13
percent.
- Net income for the quarter was $229.7 million and diluted
earnings per share was $1.56. Non-GAAP net income
increased by 7% to $235.5 million, and non-GAAP diluted
earnings per share increased by 7% to $1.60, predominantly
attributable to strong sales, partially offset by gross margin
contraction.
- Operating cash flow for the quarter was $237.4 million,
compared to net income in the current quarter of $229.7 million and
non-GAAP net income of $235.5 million. During the quarter we paid
$64.7 million in dividends.
Other Business and Operational Highlights
- Announced the acquisition of privately held Somnoware, a leader
in digital sleep and respiratory care diagnostics software for
sleep labs and physicians. Somnoware is upstream of and
complementary to ResMed’s current post-testing AirView and
Brightree offerings and will remain an open platform. The
transaction’s financial terms are not material to ResMed’s
consolidated financial results and were not disclosed.
- Supported or presented 34 clinical study abstracts at the
annual American Thoracic Society (24) and SLEEP (10) conferences,
demonstrating the breadth and depth of ResMed’s real-world evidence
that showed treating OSA with PAP lowered all-cause mortality,
adaptive-servo ventilation (ASV) improved quality of life in
central sleep apnea (CSA), and PAP adherence lowered ER visits
24-36% at 1-year for OSA patients with heart failure, among
others.
- Announced the promotion of Michael Rider to Global General
Counsel and Secretary, effective July 1, 2023 and Dawn Haake to
Chief Quality Officer, effective May 1, 2023. Mr. Rider was
previously ResMed’s Senior Vice President, Deputy Global General
Counsel and has been with ResMed for over 10 years. Ms. Haake was
previously ResMed’s Vice President, Quality Assurance and
Regulatory Affairs and has been with ResMed for 8 years.
Dividend programThe ResMed board of directors
today declared a quarterly cash dividend of $0.48 per share. The
dividend will have a record date of August 17, 2023, payable
on September 21, 2023. The dividend will be paid in U.S.
currency to holders of ResMed’s common stock trading on the New
York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”)
trading on the Australian Securities Exchange will receive an
equivalent amount in Australian currency, based on the exchange
rate on the record date, and reflecting the 10:1 ratio between CDIs
and NYSE shares. The ex-dividend date will be
August 16, 2023, for common stockholders and for CDI holders.
ResMed has received a waiver from the ASX’s settlement operating
rules, which will allow ResMed to defer processing conversions
between its common stock and CDI registers from August 16,
2023, through August 17, 2023, inclusive.
Webcast detailsResMed will discuss its
fourth-quarter fiscal year 2023 results on its webcast at 1:30 p.m.
U.S. Pacific Time today. The live webcast of the call can be
accessed on ResMed’s Investor Relations website at
investor.resmed.com. Please go to this section of the website and
click on the icon for the “Q4 2023 Earnings Webcast” to register
and listen to the live webcast. A replay of the earnings webcast
will be accessible on the website and available approximately two
hours after the live webcast. In addition, a telephone replay of
the conference call will be available approximately three hours
after the webcast by dialing +1 877-660-6853 (U.S.) or
+1 201-612-7415 (outside U.S.) and entering the passcode
13739812. The telephone replay will be available until August 17,
2023.
About ResMedAt ResMed (NYSE: RMD, ASX: RMD) we
pioneer innovative solutions that treat and keep people out of the
hospital, empowering them to live healthier, higher-quality lives.
Our digital health technologies and cloud-connected medical devices
transform care for people with sleep apnea, COPD, and other chronic
diseases. Our comprehensive out-of-hospital software
platforms support the professionals and caregivers who help people
stay healthy in the home or care setting of their choice. By
enabling better care, we improve quality of life, reduce the impact
of chronic disease, and lower costs for consumers and healthcare
systems in more than 140 countries. To learn more,
visit ResMed.com and follow @ResMed.
Safe harbor statementStatements contained in
this release that are not historical facts are “forward-looking”
statements as contemplated by the Private Securities Litigation
Reform Act of 1995. These forward-looking statements – including
statements regarding ResMed’s projections of future revenue or
earnings, expenses, new product development, new product launches,
new markets for its products, the integration of acquisitions, our
supply chain, domestic and international regulatory developments,
litigation, tax outlook, and macroeconomic conditions of our
business – are subject to risks and uncertainties, which could
cause actual results to materially differ from those projected or
implied in the forward-looking statements. Additional risks and
uncertainties are discussed in ResMed’s periodic reports on file
with the U.S. Securities & Exchange Commission. ResMed
does not undertake to update its forward-looking statements.
RESMED INC. AND SUBSIDIARIES
Condensed Consolidated Statements of
Operations(Unaudited; $ in thousands, except for per share
amounts)
|
Three Months Ended |
|
Twelve Months Ended |
|
June 30,2023 |
|
June 30,2022 |
|
June 30,2023 |
|
June 30,2022 |
|
|
|
|
|
|
|
|
Net revenue |
$ |
1,122,057 |
|
|
$ |
914,737 |
|
|
$ |
4,222,993 |
|
|
$ |
3,578,127 |
|
|
|
|
|
|
|
|
|
Cost of sales |
|
496,276 |
|
|
|
385,852 |
|
|
|
1,836,935 |
|
|
|
1,514,166 |
|
Amortization of acquired
intangibles (1) |
|
8,395 |
|
|
|
6,379 |
|
|
|
30,396 |
|
|
|
39,650 |
|
Total cost of sales |
$ |
504,671 |
|
|
$ |
392,231 |
|
|
$ |
1,867,331 |
|
|
$ |
1,553,816 |
|
Gross profit |
$ |
617,386 |
|
|
$ |
522,506 |
|
|
$ |
2,355,662 |
|
|
$ |
2,024,311 |
|
|
|
|
|
|
|
|
|
Selling, general, and
administrative |
|
240,687 |
|
|
|
193,025 |
|
|
|
874,003 |
|
|
|
737,508 |
|
Research and development |
|
78,144 |
|
|
|
64,318 |
|
|
|
287,642 |
|
|
|
253,575 |
|
Amortization of acquired
intangibles (1) |
|
12,319 |
|
|
|
7,903 |
|
|
|
42,020 |
|
|
|
31,078 |
|
Restructuring
expenses (1) |
|
9,177 |
|
|
|
— |
|
|
|
9,177 |
|
|
|
— |
|
Acquisition related expenses
(1) |
|
1,792 |
|
|
|
1,864 |
|
|
|
10,949 |
|
|
|
1,864 |
|
Total operating expenses |
$ |
342,119 |
|
|
$ |
267,110 |
|
|
$ |
1,223,791 |
|
|
$ |
1,024,025 |
|
Income from operations |
$ |
275,267 |
|
|
$ |
255,396 |
|
|
$ |
1,131,871 |
|
|
$ |
1,000,286 |
|
|
|
|
|
|
|
|
|
Other income (expenses),
net: |
|
|
|
|
|
|
|
Interest income (expense),
net |
$ |
(14,943 |
) |
|
$ |
(5,542 |
) |
|
$ |
(47,379 |
) |
|
$ |
(22,312 |
) |
Loss attributable to equity
method investments |
|
(2,228 |
) |
|
|
(2,558 |
) |
|
|
(7,265 |
) |
|
|
(8,486 |
) |
Gain (loss) on equity
investments (1) |
|
(1,583 |
) |
|
|
(11,675 |
) |
|
|
9,922 |
|
|
|
(12,202 |
) |
Gain on insurance recoveries
(1) |
|
20,227 |
|
|
|
— |
|
|
|
20,227 |
|
|
|
— |
|
Other, net |
|
61 |
|
|
|
2,468 |
|
|
|
(5,712 |
) |
|
|
3,197 |
|
Total other income (expenses),
net |
|
1,534 |
|
|
|
(17,307 |
) |
|
|
(30,207 |
) |
|
|
(39,803 |
) |
Income before income
taxes |
$ |
276,801 |
|
|
$ |
238,089 |
|
|
$ |
1,101,664 |
|
|
$ |
960,483 |
|
Income taxes |
|
47,137 |
|
|
|
43,028 |
|
|
|
204,108 |
|
|
|
181,046 |
|
Net income |
$ |
229,664 |
|
|
$ |
195,061 |
|
|
$ |
897,556 |
|
|
$ |
779,437 |
|
|
|
|
|
|
|
|
|
Basic earnings per share |
$ |
1.56 |
|
|
$ |
1.33 |
|
|
$ |
6.12 |
|
|
$ |
5.34 |
|
Diluted earnings per
share |
$ |
1.56 |
|
|
$ |
1.33 |
|
|
$ |
6.09 |
|
|
$ |
5.30 |
|
Non-GAAP diluted earnings
per share (1) |
$ |
1.60 |
|
|
$ |
1.49 |
|
|
$ |
6.44 |
|
|
$ |
5.79 |
|
|
|
|
|
|
|
|
|
Basic shares outstanding |
|
147,015 |
|
|
|
146,361 |
|
|
|
146,765 |
|
|
|
146,066 |
|
Diluted shares
outstanding |
|
147,554 |
|
|
|
147,000 |
|
|
|
147,455 |
|
|
|
147,043 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) See the reconciliation of non-GAAP financial
measures in the table at the end of the press release.
Condensed Consolidated Balance
Sheets(Unaudited; $ in thousands)
|
June 30,2023 |
|
June 30,2022 |
Assets |
|
|
|
Current assets: |
|
|
|
Cash and cash equivalents |
$ |
227,891 |
|
|
$ |
273,710 |
|
Accounts receivable, net |
|
704,909 |
|
|
|
575,950 |
|
Inventories |
|
998,012 |
|
|
|
743,910 |
|
Prepayments and other current assets |
|
437,018 |
|
|
|
337,908 |
|
Total current assets |
$ |
2,367,830 |
|
|
$ |
1,931,478 |
|
Non-current assets: |
|
|
|
Property, plant, and equipment, net |
$ |
537,856 |
|
|
$ |
498,181 |
|
Operating lease right-of-use assets |
|
127,955 |
|
|
|
132,314 |
|
Goodwill and other intangibles, net |
|
3,322,640 |
|
|
|
2,282,386 |
|
Deferred income taxes and other non-current assets |
|
395,427 |
|
|
|
251,494 |
|
Total non-current assets |
$ |
4,383,878 |
|
|
$ |
3,164,375 |
|
Total assets |
$ |
6,751,708 |
|
|
$ |
5,095,853 |
|
Liabilities and
Stockholders’ Equity |
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
$ |
150,756 |
|
|
$ |
159,245 |
|
Accrued expenses |
|
365,660 |
|
|
|
344,722 |
|
Operating lease liabilities, current |
|
21,919 |
|
|
|
21,856 |
|
Deferred revenue |
|
138,072 |
|
|
|
108,667 |
|
Income taxes payable |
|
72,224 |
|
|
|
44,893 |
|
Short-term debt |
|
9,902 |
|
|
|
9,916 |
|
Total current liabilities |
$ |
758,533 |
|
|
$ |
689,299 |
|
Non-current liabilities: |
|
|
|
Deferred revenue |
$ |
119,186 |
|
|
$ |
95,455 |
|
Deferred income taxes |
|
90,650 |
|
|
|
9,714 |
|
Operating lease liabilities, non-current |
|
116,853 |
|
|
|
120,453 |
|
Other long-term liabilities |
|
68,166 |
|
|
|
5,974 |
|
Long-term debt |
|
1,431,234 |
|
|
|
765,325 |
|
Long-term income taxes payable |
|
37,183 |
|
|
|
48,882 |
|
Total non-current liabilities |
$ |
1,863,272 |
|
|
$ |
1,045,803 |
|
Total liabilities |
$ |
2,621,805 |
|
|
$ |
1,735,102 |
|
Stockholders’ equity |
|
|
|
Common stock |
$ |
588 |
|
|
$ |
586 |
|
Additional paid-in capital |
|
1,772,083 |
|
|
|
1,682,432 |
|
Retained earnings |
|
4,253,016 |
|
|
|
3,613,736 |
|
Treasury stock |
|
(1,623,256 |
) |
|
|
(1,623,256 |
) |
Accumulated other comprehensive income |
|
(272,528 |
) |
|
|
(312,747 |
) |
Total stockholders’
equity |
$ |
4,129,903 |
|
|
$ |
3,360,751 |
|
Total liabilities and
stockholders’ equity |
$ |
6,751,708 |
|
|
$ |
5,095,853 |
|
|
|
|
|
|
|
|
|
Condensed Consolidated Statements of Cash
Flows(Unaudited; $ in thousands)
|
Three Months Ended |
|
Twelve Months Ended |
|
June 30,2023 |
|
June 30,2022 |
|
June 30,2023 |
|
June 30,2022 |
Cash flows from
operating activities: |
|
|
|
|
|
|
|
Net income |
$ |
229,664 |
|
|
$ |
195,061 |
|
|
$ |
897,556 |
|
|
$ |
779,437 |
|
Adjustment to reconcile net
income to cash provided by operating activities: |
|
|
|
|
|
|
|
Depreciation and
amortization |
|
46,760 |
|
|
|
37,411 |
|
|
|
165,156 |
|
|
|
159,609 |
|
Amortization
of right-of-use assets |
|
8,440 |
|
|
|
7,596 |
|
|
|
32,406 |
|
|
|
34,232 |
|
Stock-based compensation
costs |
|
19,927 |
|
|
|
15,993 |
|
|
|
71,142 |
|
|
|
65,257 |
|
Loss attributable to equity
method investments, net of dividends received |
|
5,102 |
|
|
|
2,558 |
|
|
|
10,138 |
|
|
|
8,486 |
|
(Gain) loss on equity
investment |
|
1,584 |
|
|
|
11,675 |
|
|
|
(9,922 |
) |
|
|
12,202 |
|
Restructuring expenses |
|
9,177 |
|
|
|
— |
|
|
|
9,177 |
|
|
|
— |
|
Gain on insurance
recoveries |
|
(20,227 |
) |
|
|
— |
|
|
|
(20,227 |
) |
|
|
— |
|
Changes in operating assets
and liabilities: |
|
|
|
|
|
|
|
Accounts receivable, net |
|
(18,059 |
) |
|
|
(78,812 |
) |
|
|
(106,511 |
) |
|
|
19,346 |
|
Inventories, net |
|
6,257 |
|
|
|
(102,205 |
) |
|
|
(248,833 |
) |
|
|
(311,681 |
) |
Prepaid expenses, net deferred
income taxes and other current assets |
|
(51,518 |
) |
|
|
(40,132 |
) |
|
|
(138,125 |
) |
|
|
(168,109 |
) |
Accounts payable, accrued
expenses, income taxes payable and other |
|
330 |
|
|
|
30,343 |
|
|
|
31,342 |
|
|
|
(247,632 |
) |
Net cash provided by operating
activities |
$ |
237,437 |
|
|
$ |
79,488 |
|
|
$ |
693,299 |
|
|
$ |
351,147 |
|
Cash flows from
investing activities: |
|
|
|
|
|
|
|
Purchases of property, plant,
and equipment |
|
(34,449 |
) |
|
|
(28,643 |
) |
|
|
(119,672 |
) |
|
|
(134,835 |
) |
Patent registration and
acquisition costs |
|
(4,285 |
) |
|
|
(3,752 |
) |
|
|
(14,328 |
) |
|
|
(21,201 |
) |
Business acquisitions, net of
cash acquired |
|
(1,524 |
) |
|
|
(6,870 |
) |
|
|
(1,012,749 |
) |
|
|
(42,784 |
) |
Purchases of investments |
|
(2,500 |
) |
|
|
(4,110 |
) |
|
|
(32,229 |
) |
|
|
(20,724 |
) |
Proceeds from exits of
investments |
|
— |
|
|
|
— |
|
|
|
3,937 |
|
|
|
6,802 |
|
(Payments) / proceeds on
maturity of foreign currency contracts |
|
(3,765 |
) |
|
|
(11,867 |
) |
|
|
15,196 |
|
|
|
(17,176 |
) |
Net cash used in investing
activities |
$ |
(46,523 |
) |
|
$ |
(55,242 |
) |
|
$ |
(1,159,845 |
) |
|
$ |
(229,918 |
) |
Cash flows from
financing activities: |
|
|
|
|
|
|
|
Proceeds from issuance of
common stock, net |
|
23,493 |
|
|
|
21,114 |
|
|
|
49,142 |
|
|
|
47,384 |
|
Taxes paid related to net
share settlement of equity awards |
|
(334 |
) |
|
|
(128 |
) |
|
|
(30,631 |
) |
|
|
(52,406 |
) |
Payments of business
combination contingent consideration |
|
(2,045 |
) |
|
|
— |
|
|
|
(2,361 |
) |
|
|
— |
|
Proceeds from borrowings, net
of borrowing costs |
|
— |
|
|
|
128,000 |
|
|
|
1,070,000 |
|
|
|
288,000 |
|
Repayment of borrowings |
|
(145,000 |
) |
|
|
(30,000 |
) |
|
|
(405,000 |
) |
|
|
(166,000 |
) |
Dividends paid |
|
(64,705 |
) |
|
|
(61,488 |
) |
|
|
(258,276 |
) |
|
|
(245,341 |
) |
Net cash (used in) / provided
by financing activities |
$ |
(188,591 |
) |
|
$ |
57,498 |
|
|
$ |
422,874 |
|
|
$ |
(128,363 |
) |
Effect of exchange rate
changes on cash |
$ |
(2,326 |
) |
|
$ |
(9,803 |
) |
|
$ |
(2,147 |
) |
|
$ |
(14,434 |
) |
Net increase / (decrease) in
cash and cash equivalents |
|
(3 |
) |
|
|
71,941 |
|
|
|
(45,819 |
) |
|
|
(21,568 |
) |
Cash and cash equivalents at
beginning of period |
|
227,894 |
|
|
|
201,769 |
|
|
|
273,710 |
|
|
|
295,278 |
|
Cash and cash
equivalents at end of period |
$ |
227,891 |
|
|
$ |
273,710 |
|
|
$ |
227,891 |
|
|
$ |
273,710 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of Non-GAAP Financial
Measures(Unaudited; $ in thousands, except for per share
amounts)
The measures “non-GAAP gross profit”
and “non-GAAP gross margin” exclude amortization expense
from acquired intangibles and restructuring expense related to cost
of sales and are reconciled below:
|
Three Months Ended |
|
Twelve Months Ended |
|
June 30, 2023 |
|
June 30, 2022 |
|
June 30, 2023 |
|
June 30, 2022 |
|
|
|
|
|
|
|
|
Revenue |
$ |
1,122,057 |
|
|
$ |
914,737 |
|
|
$ |
4,222,993 |
|
|
$ |
3,578,127 |
|
|
|
|
|
|
|
|
|
GAAP cost of sales |
$ |
504,671 |
|
|
$ |
392,231 |
|
|
$ |
1,867,331 |
|
|
$ |
1,553,816 |
|
Less: Amortization of
acquired intangibles (A) |
|
(8,395 |
) |
|
|
(6,379 |
) |
|
|
(30,396 |
) |
|
|
(39,650 |
) |
Non-GAAP cost of
sales |
$ |
496,276 |
|
|
$ |
385,852 |
|
|
$ |
1,836,935 |
|
|
$ |
1,514,166 |
|
|
|
|
|
|
|
|
|
GAAP gross profit |
$ |
617,386 |
|
|
$ |
522,506 |
|
|
$ |
2,355,662 |
|
|
$ |
2,024,311 |
|
GAAP gross margin |
|
55.0 |
% |
|
|
57.1 |
% |
|
|
55.8 |
% |
|
|
56.6 |
% |
Non-GAAP gross
profit |
$ |
625,781 |
|
|
$ |
528,885 |
|
|
$ |
2,386,058 |
|
|
$ |
2,063,961 |
|
Non-GAAP gross
margin |
|
55.8 |
% |
|
|
57.8 |
% |
|
|
56.5 |
% |
|
|
57.7 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The measure “non-GAAP income from operations” is
reconciled with GAAP income from operations below:
|
Three Months Ended |
|
Twelve Months Ended |
|
June 30, 2023 |
|
June 30, 2022 |
|
June 30, 2023 |
|
June 30, 2022 |
|
|
|
|
|
|
|
|
GAAP income from operations |
$ |
275,267 |
|
|
$ |
255,396 |
|
|
$ |
1,131,871 |
|
|
$ |
1,000,286 |
|
Amortization of acquired
intangibles—cost of sales (A) |
|
8,395 |
|
|
|
6,379 |
|
|
|
30,396 |
|
|
|
39,650 |
|
Amortization of acquired
intangibles—operating expenses (A) |
|
12,319 |
|
|
|
7,903 |
|
|
|
42,020 |
|
|
|
31,078 |
|
Restructuring (A) |
|
9,177 |
|
|
|
— |
|
|
|
9,177 |
|
|
|
— |
|
Acquisition-related expenses (A) |
|
1,792 |
|
|
|
1,864 |
|
|
|
10,949 |
|
|
|
1,864 |
|
Non-GAAP income from
operations |
$ |
306,950 |
|
|
$ |
271,542 |
|
|
$ |
1,224,413 |
|
|
$ |
1,072,878 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reconciliation of Non-GAAP Financial
Measures(Unaudited; $ in thousands, except for per share
amounts)
The measures “non-GAAP net income”
and “non-GAAP diluted earnings per share” are reconciled
with GAAP net income and GAAP diluted earnings per share in the
table below:
|
Three Months Ended |
|
Twelve Months Ended |
|
June 30, 2023 |
|
June 30, 2022 |
|
June 30, 2023 |
|
June 30, 2022 |
|
|
|
|
|
|
|
|
GAAP net income |
$ |
229,664 |
|
|
$ |
195,061 |
|
|
$ |
897,556 |
|
|
$ |
779,437 |
|
Amortization of acquired intangibles—cost of sales (A) |
|
8,395 |
|
|
|
6,379 |
|
|
|
30,396 |
|
|
|
39,650 |
|
Amortization of acquired intangibles—operating
expenses (A) |
|
12,319 |
|
|
|
7,903 |
|
|
|
42,020 |
|
|
|
31,078 |
|
Restructuring expenses (A) |
|
9,177 |
|
|
|
— |
|
|
|
9,177 |
|
|
|
— |
|
Acquisition-related expenses (A) |
|
1,792 |
|
|
|
1,864 |
|
|
|
10,949 |
|
|
|
1,864 |
|
Gain on
insurance recoveries (A) |
|
(20,227 |
) |
|
|
— |
|
|
|
(20,227 |
) |
|
|
— |
|
(Gain)
loss on equity investments (A) |
|
— |
|
|
|
11,675 |
|
|
|
— |
|
|
|
11,675 |
|
Reserve
for disputed tax position (A) |
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
4,111 |
|
Income
tax effect on non-GAAP adjustments (A) |
|
(5,631 |
) |
|
|
(3,644 |
) |
|
|
(20,114 |
) |
|
|
(17,044 |
) |
Non-GAAP net income (A) |
$ |
235,489 |
|
|
$ |
219,238 |
|
|
$ |
949,757 |
|
|
$ |
850,771 |
|
|
|
|
|
|
|
|
|
GAAP
diluted shares outstanding |
|
147,554 |
|
|
|
147,000 |
|
|
|
147,455 |
|
|
|
147,043 |
|
GAAP
diluted earnings per share |
$ |
1.56 |
|
|
$ |
1.33 |
|
|
$ |
6.09 |
|
|
$ |
5.30 |
|
Non-GAAP diluted earnings per share (A) |
$ |
1.60 |
|
|
$ |
1.49 |
|
|
$ |
6.44 |
|
|
$ |
5.79 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(A) ResMed adjusts for the impact of the amortization of
acquired intangibles, restructuring expenses, acquisition-related
expenses, gain on insurance recoveries, (gain) loss on equity
investments, reserves for disputed tax positions, and associated
tax effects from their evaluation of ongoing operations, and
believes that investors benefit from adjusting these items to
facilitate a more meaningful evaluation of current operating
performance.
ResMed believes that non-GAAP diluted earnings per
share is an additional measure of performance that investors can
use to compare operating results between reporting periods. ResMed
uses non-GAAP information internally in planning,
forecasting, and evaluating the results of operations in the
current period and in comparing it to past periods. ResMed believes
this information provides investors better insight when evaluating
ResMed’s performance from core operations and provides consistent
financial reporting. The use of non-GAAP measures is
intended to supplement, and not to replace, the presentation of net
income and other GAAP measures. Like
all non-GAAP measures, non-GAAP earnings are
subject to inherent limitations because they do not include all the
expenses that must be included under GAAP.
Revenue by Product and Region(Unaudited; $ in
millions, except for per share amounts)
|
Three Months Ended |
|
June 30,2023 |
(A) |
June 30,2022 |
(A) |
% Change |
|
ConstantCurrency (B) |
U.S., Canada, and
Latin America |
|
|
|
|
|
|
|
Devices |
$ |
387.2 |
|
|
$ |
298.9 |
|
|
|
30 |
% |
|
|
Masks and other |
|
273.7 |
|
|
|
229.6 |
|
|
|
19 |
|
|
|
Total U.S., Canada and Latin
America |
$ |
660.9 |
|
|
$ |
528.5 |
|
|
|
25 |
|
|
|
|
|
|
|
|
|
|
|
Combined Europe, Asia,
and other markets |
|
|
|
|
|
|
|
Devices |
$ |
215.2 |
|
|
$ |
188.2 |
|
|
|
14 |
% |
|
|
15 |
% |
Masks and other |
|
107.4 |
|
|
|
94.9 |
|
|
|
13 |
|
|
|
14 |
|
Total Combined Europe, Asia
and other markets |
$ |
322.6 |
|
|
$ |
283.1 |
|
|
|
14 |
|
|
|
14 |
|
|
|
|
|
|
|
|
|
Global
revenue |
|
|
|
|
|
|
|
Total Devices |
$ |
602.4 |
|
|
$ |
487.2 |
|
|
|
24 |
% |
|
|
24 |
% |
Total Masks and other |
|
381.0 |
|
|
|
324.4 |
|
|
|
17 |
|
|
|
18 |
|
Total Sleep and
Respiratory Care |
$ |
983.5 |
|
|
$ |
811.6 |
|
|
|
21 |
|
|
|
21 |
|
|
|
|
|
|
|
|
|
Software-as-a-Service |
|
138.6 |
|
|
|
103.1 |
|
|
|
34 |
|
|
|
Total |
$ |
1,122.1 |
|
|
$ |
914.7 |
|
|
|
23 |
|
|
|
23 |
|
|
Twelve Months Ended |
|
June 30,2023 |
(A) |
June 30,2022 |
(A) |
%Change |
|
ConstantCurrency (B) |
U.S., Canada, and
Latin America |
|
|
|
|
|
|
|
Devices |
$ |
1,444.4 |
|
|
$ |
1,070.4 |
|
|
|
35 |
% |
|
|
Masks and other |
|
1,039.0 |
|
|
|
911.4 |
|
|
|
14 |
|
|
|
Total U.S., Canada and Latin
America |
$ |
2,483.4 |
|
|
$ |
1,981.8 |
|
|
|
25 |
|
|
|
|
|
|
|
|
|
|
|
Combined Europe, Asia,
and other markets |
|
|
|
|
|
|
|
Devices |
$ |
826.3 |
|
|
$ |
796.5 |
|
|
|
4 |
% |
|
|
11 |
% |
Masks and other |
|
415.3 |
|
|
|
399.0 |
|
|
|
4 |
|
|
|
12 |
|
Total Combined Europe, Asia
and other markets |
$ |
1,241.6 |
|
|
$ |
1,195.5 |
|
|
|
4 |
|
|
|
11 |
|
|
|
|
|
|
|
|
|
Global
revenue |
|
|
|
|
|
|
|
Total Devices |
$ |
2,270.7 |
|
|
$ |
1,866.9 |
|
|
|
22 |
% |
|
|
25 |
% |
Total Masks and other |
|
1,454.3 |
|
|
|
1,310.4 |
|
|
|
11 |
|
|
|
14 |
|
Total Sleep and
Respiratory Care |
$ |
3,725.0 |
|
|
$ |
3,177.3 |
|
|
|
17 |
|
|
|
20 |
|
|
|
|
|
|
|
|
|
Software-as-a-Service |
|
498.0 |
|
|
|
400.8 |
|
|
|
24 |
|
|
|
Total |
$ |
4,223.0 |
|
|
$ |
3,578.1 |
|
|
|
18 |
|
|
|
21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(A) Totals and subtotals may not add due to rounding.
(B) In order to provide a framework for assessing how our
underlying businesses performed excluding the effect of foreign
currency fluctuations, we provide certain financial information on
a “constant currency basis,” which is in addition to the actual
financial information presented. In order to calculate our constant
currency information, we translate the current period financial
information using the foreign currency exchange rates that were in
effect during the previous comparable period. However, constant
currency measures should not be considered in isolation or as an
alternative to U.S. dollar measures that reflect current period
exchange rates, or to other financial measures calculated and
presented in accordance with U.S. GAAP.
For investors+1
858-836-5000investorrelations@resmed.com |
|
For media+1 858-289-7272news@resmed.com |
|
|
|
ResMed (NYSE:RMD)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
ResMed (NYSE:RMD)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024